Latest filings (excl ownership)
6-K
Inspira™ Receives CSA Certification of Compliance to U.S. Standards for the INSPIRA™ ART100
25 Apr 24
6-K
Inspira™ Signs Term Sheet for Use of INSPIRA™ ART100 Device in Organ Transplant Procedures
17 Apr 24
6-K
Inspira™ and Ennocure In Vitro Study Results Show 100% Prevention of Bacterial Growth that Causes Bloodstream Infections
10 Apr 24
6-K
Report of Foreign Private Issuer
9 Apr 24
6-K
Inspira™ Announces Program to Pioneer the Applicable Use of the INSPIRA™ ART100 Device for an Artificial Womb
3 Apr 24
424B5
Prospectus supplement for primary offering
1 Apr 24
6-K
Inspira™ Announces $1.65 Million Registered Direct Offering of Ordinary Shares by Inspira CEO’s Mother with Leading Fund Manager
1 Apr 24
6-K
Inspira™ Technologies Reports Full Year 2023 Financial Results
25 Mar 24
20-F
2023 FY
Annual report (foreign)
25 Mar 24
6-K
Inspira™ Announces AMAR Regulatory Submission of the INSPIRA™ ART100, to Enter the Southeast Asia and South American Markets
18 Mar 24
S-8
Registration of securities for employees
15 Mar 24
6-K
Inspira™ Releases New Data Demonstrating Superiority of its Core Technology, Across Key Endpoints of HMSS Indicator
12 Mar 24
6-K
Notice of Extraordinary General Meeting of Shareholders
8 Mar 24
6-K
Notice of Extraordinary General Meeting of Shareholders
4 Mar 24
6-K
Inspira™ Announces Plans to Report the Primary Results for a Core Blood Oxygenation Technology Within Days
4 Mar 24
6-K
Report of Foreign Private Issuer
27 Feb 24
6-K
Inspira™ introduces high-end platform for bio-mimicking blood parameters for development and testing of core technologies
22 Feb 24
6-K
Inspira™ Receives First Ever U.S. Patent Approval for an Orbiting Blood Oxygenation Delivery System
14 Feb 24
6-K
Report of Foreign Private Issuer
8 Feb 24
6-K
Inspira™ Technologies Signs Strategic Agreement to Enter Gulf States with Glo-Med for Deployment of 531 INSPIRA™ ART Devices
30 Jan 24
6-K
Inspira™ Announces Plans to Launch and Target Single-Use Disposable Blood Oxygenation Kit for a New Disposable Perfusion Market Opportunity
9 Jan 24
6-K
Inspira™ Technologies Signs Letter of Intent with Northwestern Memorial Hospital in Chicago for Clinical Use of INSPIRA™ ART100 Device
2 Jan 24
6-K
Report of Foreign Private Issuer
28 Dec 23
424B5
Prospectus supplement for primary offering
28 Dec 23
6-K
Inspira Announces $3.88 Million Registered Direct Offering
27 Dec 23
6-K
Inspira™ Announces 95% Accuracy Results for HYLA™ Blood Sensor, Planning FDA Submission for Clearance in 2024
26 Dec 23
6-K
In Preparation for FDA Clearance and Device Deployment, Inspira has Appointed Dr. Dan Gorfil to Medical Advisory Board
11 Dec 23
6-K
Report of Foreign Private Issuer
29 Nov 23
6-K
Notice of Annual General Meeting of Shareholders
22 Nov 23
6-K
Inspira™ Technologies Reports Third Quarter 2023 Financial Results
16 Nov 23
6-K
Current Report
13 Nov 23
6-K
Inspira™ Announces Israeli Innovation Authority Grant for New VORTX™ Disposable Blood Oxygenation Technology
7 Nov 23
424B3
Prospectus supplement
25 Oct 23
6-K
Inspira™ Granted U.S. Patent for INSPIRA™ ART500 Medical Device
25 Oct 23
6-K
Inspira™ Terminates ATM Program and Provides an Update
24 Oct 23
6-K
Inspira™ Enters into a Distribution Agreement in Central America with CIO MED GROUP
10 Oct 23
POS AM
Prospectus update (post-effective amendment)
10 Oct 23
6-K
Interim Condensed Financial Statements
2 Oct 23
6-K
Inspira™ Technologies Unveils the INSPIRA™ ART Line of Medical Devices at the World’s Largest Extracorporeal Life Support Conference
28 Sep 23
6-K
InspiraTM Announces 510(k) FDA Submission of INSPIRATM ART100 Towards Commercialization
13 Sep 23